Cyted Health, a privately held molecular diagnostics company developing non-endoscopic tests for esophageal disease, announced on October 14, 2026, that its EndoSign Barrett’s Esophagus Test achieved 90% sensitivity and 86% specificity in a prospective United States clinical validation study involving 324 participants. The DETECT-ME investigation, conducted across 18 clinical sites, compared results from Cyted’s capsule sponge collection device and DNA methylation assay against conventional endoscopy and biopsy.
The company also reported 100% sensitivity for detecting dysplasia and esophageal adenocarcinoma within the evaluated population, alongside 99% sensitivity for long-segment Barrett’s esophagus. Successful cell collection was achieved in approximately 95% of participants, with no device-related adverse events reported. Most patients tolerated the procedure favorably, and 82% rated their experience as excellent.
The findings were presented as late-breaking research at the American College of Gastroenterology’s 2026 Annual Scientific Meeting in Nashville. They provide additional United States evidence for a diagnostic approach designed to identify patients who should undergo confirmatory endoscopy without requiring everyone to begin with a sedated hospital-based procedure.
However, several distinctions are important. The EndoSign cell collection device received FDA 510(k) clearance in January 2024, while the associated methylation-based Barrett’s esophagus test is a laboratory-developed test performed in Cyted’s CLIA-certified, CAP-accredited laboratory. The molecular assay itself has not received FDA clearance or approval, and the reported findings do not establish that EndoSign can replace confirmatory endoscopy or reduce deaths from esophageal cancer.
What did the DETECT-ME study establish about EndoSign’s diagnostic accuracy?
DETECT-ME was designed to evaluate whether a non-endoscopic sampling device combined with molecular analysis could reliably identify Barrett’s esophagus in a United States clinical population. Its prospective, multicenter structure is important because diagnostic performance can vary between healthcare settings and patient groups. Comparing the assay directly with endoscopy and biopsy provides a clinically relevant reference standard for assessing disease detection.
The reported 90% sensitivity indicates that the test identified approximately nine out of ten patients who had Barrett’s esophagus under the study’s reference diagnosis. The 86% specificity indicates that approximately 86% of participants without the condition were correctly classified as negative. Both measures help describe test performance, although neither represents the probability that every positive result is a true diagnosis.
A sensitivity of 90% also means that some patients with Barrett’s esophagus were not detected by the test. The implications of a negative result therefore depend on an individual’s clinical circumstances and underlying risk. Cyted’s own provider information states that a negative EndoSign result does not rule out the disease.
The study’s results are encouraging, particularly because the investigation included 18 US sites rather than relying exclusively on a single institution. However, the October announcement does not provide complete confidence intervals, detailed subgroup denominators or the full distribution of patient characteristics. These additional details are necessary to assess the precision of the results and determine how closely the evaluated population resembles patients encountered in routine primary care.
Diagnostic accuracy in a study population also does not automatically establish effectiveness in a general screening programme. Performance must be considered alongside the prevalence of disease, the consequences of false-positive and false-negative results, and whether testing changes subsequent clinical decisions.
Why does the reported 100% sensitivity for dysplasia and esophageal cancer require careful interpretation?
Cyted reported that EndoSign detected all cases of dysplasia and esophageal adenocarcinoma included in the relevant analysis. This is particularly interesting because these conditions are associated with greater clinical concern than nondysplastic Barrett’s esophagus. Identifying them before progression can create opportunities for appropriate evaluation, surveillance and treatment.
However, the company has not disclosed the number of dysplasia and cancer cases underlying the reported 100% sensitivity figure. That denominator matters because identifying every case in a small subgroup is statistically different from demonstrating the same performance in a much larger population. The reported percentage should therefore not be presented as evidence that EndoSign will never miss dysplasia or cancer.
Similarly, the 99% sensitivity for long-segment Barrett’s esophagus suggests strong performance in patients with more extensive disease. Long-segment Barrett’s generally involves a larger area of abnormal esophageal lining than short-segment disease, which could influence the amount of abnormal cellular material collected. The announcement does not establish that detection is equally reliable across every disease length and histological subgroup.
The distinction is particularly important when evaluating early detection strategies. Short-segment Barrett’s esophagus can account for a substantial proportion of diagnosed cases, and the test’s performance in patients with smaller areas of disease will affect its usefulness in broader populations. The overall sensitivity of 90% should therefore remain central to interpretation rather than being overshadowed by the strongest subgroup results.
The next level of evidence would include a complete study publication showing patient numbers, confidence intervals and diagnostic performance across disease categories. Independent replication could further establish whether the reported accuracy is maintained across different populations and clinical workflows.
How does the EndoSign capsule sponge collect esophageal cells without sedation?
The EndoSign system uses a small capsule containing a compressed sponge attached to a string. The patient swallows the capsule, which dissolves in the stomach and releases the sponge. A healthcare professional then withdraws the sponge using the attached string, allowing it to collect cells from the lining of the esophagus.
The collected material is placed in a preservation system and transported to a laboratory for analysis. Because the procedure does not involve inserting a conventional endoscope, it can be performed without the sedation typically used for many upper gastrointestinal endoscopy procedures. This creates an opportunity to offer an initial test in clinical environments where immediate endoscopic examination is not available.
The collection device obtained FDA 510(k) clearance on January 19, 2024, under submission K233142. That clearance covers the device’s intended role in esophageal cell collection. It should not be confused with FDA clearance of the DNA methylation assay used to analyze the resulting sample.
The DETECT-ME study achieved sampling success in approximately 95% of participants, suggesting that the procedure produced usable specimens in most of the evaluated patients. No device-related adverse events were reported, while 82% rated the experience as excellent. These observations provide supportive information about feasibility and tolerability within the investigated setting.
Nevertheless, the procedure may not be suitable for every patient. Swallowing difficulties, anatomical abnormalities, certain previous surgical procedures and other medical conditions may influence eligibility. Appropriate patient selection and adherence to the device’s instructions remain important.
What role does DNA methylation play in EndoSign’s Barrett’s esophagus test?
EndoSign combines physical cell collection with a molecular test designed to detect DNA methylation patterns associated with Barrett’s esophagus. DNA methylation is a biological process that can influence gene regulation without changing the underlying DNA sequence. Altered methylation patterns have been observed in several cancers and precancerous conditions.
Barrett’s esophagus develops when the normal squamous lining of the lower esophagus is replaced by a different type of tissue, often associated with chronic gastroesophageal reflux disease. Molecular changes can occur during the development and progression of this abnormal lining. Detecting selected methylation signals provides a potential way to identify tissue associated with Barrett’s disease without first performing an endoscopic biopsy.
Cyted’s test analyzes material collected from the esophagus for a defined set of methylation biomarkers. The resulting information is used to estimate whether a sample contains molecular characteristics associated with Barrett’s esophagus. This is different from direct microscopic examination of a tissue biopsy, which remains central to confirming the diagnosis.
The molecular approach is scientifically attractive because it may identify abnormal cellular patterns from samples collected across the esophageal surface. However, biomarker results can be affected by sample quality, disease distribution and the assay’s ability to distinguish affected from unaffected tissue. A positive molecular signal must therefore be interpreted within the broader diagnostic pathway.
The test is intended to guide decisions about referral for confirmatory endoscopy. It does not independently establish the grade of dysplasia, determine cancer stage or replace the tissue analysis needed for definitive clinical management.
Why could non-endoscopic screening help address underdiagnosis of Barrett’s esophagus?
Barrett’s esophagus is associated with an increased risk of esophageal adenocarcinoma, a cancer that can be difficult to treat when diagnosed at an advanced stage. Most people with Barrett’s esophagus do not progress to cancer, but identifying the condition can allow appropriate surveillance and treatment of precancerous changes. The challenge is determining which individuals are most likely to benefit from screening.
Conventional diagnosis usually requires upper gastrointestinal endoscopy, during which a clinician visually examines the esophagus and obtains biopsies where indicated. Although this provides important diagnostic information, the procedure requires specialized equipment, clinical resources and patient preparation. These factors can limit access, particularly when large numbers of people have reflux symptoms but only a minority have Barrett’s esophagus.
Current American College of Gastroenterology guidance suggests screening for selected individuals with chronic reflux and multiple additional risk factors. The guideline also recognizes swallowable non-endoscopic capsule devices combined with biomarkers as an acceptable alternative to endoscopy for initial screening, although the quality of supporting evidence has historically been limited.
EndoSign is intended to provide a less invasive initial assessment for patients considered at increased risk. Cyted’s United States provider information identifies individuals with combinations of factors including age, sex, chronic reflux, obesity, smoking history and family history. It is not positioned as a universal screening test for every adult.
A potential benefit is more selective use of endoscopy. Patients with a positive molecular signal could be referred for confirmatory investigation, while negative results may help inform further assessment when considered alongside clinical risk. However, the effect on referral volumes, healthcare costs and cancer outcomes must be studied rather than assumed.
How should clinicians interpret positive and negative EndoSign results?
A positive EndoSign result indicates that the assay detected molecular characteristics associated with Barrett’s esophagus. It does not constitute a definitive diagnosis and requires appropriate confirmatory evaluation through endoscopy. This distinction is essential because molecular diagnostic tests can produce false-positive results even when specificity is relatively high.
An 86% specificity means that approximately 14% of individuals without Barrett’s esophagus in the validation comparison could produce a positive result. In a population where disease prevalence is low, those false positives can represent a substantial proportion of all positive test results. The actual positive predictive value therefore depends on how frequently Barrett’s esophagus occurs in the population being tested.
Negative results also require care. A test with 90% sensitivity can miss some individuals who have the condition, and a negative molecular result should not override significant clinical concerns. Physicians must consider symptoms, risk factors and whether conventional endoscopy remains indicated for other reasons.
The practical value of EndoSign will depend on how these results are incorporated into care pathways. A test that appropriately identifies high-risk patients could improve access to further evaluation, but unnecessary endoscopy following false-positive findings would create additional healthcare use. The optimal balance will depend on the test’s performance in the populations for which it is offered.
How does the new US validation build on earlier capsule sponge research?
Non-endoscopic esophageal cell collection has been investigated for more than a decade, including substantial research conducted in the United Kingdom. One influential randomized study, BEST3, evaluated a capsule sponge test combined with the trefoil factor 3 biomarker in patients receiving treatment for gastroesophageal reflux. The study involved more than 13,000 participants allocated to testing or usual care.
The investigators reported 140 Barrett’s esophagus diagnoses in the intervention group compared with 13 in the usual-care group over approximately one year. The adjusted rate ratio was 10.6, providing evidence that offering a non-endoscopic test could increase diagnosis among appropriately selected patients. However, that study used a different biomarker approach and should not be treated as direct validation of Cyted’s current methylation assay.
The broader research programme helped demonstrate the feasibility of collecting esophageal cells outside conventional endoscopy. It also established that a screening strategy must be evaluated in terms of actual diagnoses and subsequent clinical management, rather than analytical accuracy alone. The current DETECT-ME results contribute additional evidence about test accuracy in a United States population.
Cyted says its diagnostic platform has been used for more than 40,000 tests across its wider commercial and clinical experience. That figure reflects platform activity rather than the size of the DETECT-ME validation cohort. The new study’s 324 participants provide a separate, prospectively collected dataset for evaluating the specific US test.
What regulatory and reimbursement hurdles remain for wider US adoption?
The United States regulatory position includes two distinct components. The EndoSign cell collection device is FDA 510(k)-cleared, while the associated Barrett’s esophagus molecular assay is offered as a laboratory-developed test. Cyted states that the assay is performed in a CLIA-certified, CAP-accredited laboratory and has not been cleared or approved by the FDA.
CLIA certification establishes requirements for laboratory testing quality and competence within the applicable framework. It does not represent an FDA determination that a particular molecular assay is safe or effective for every proposed clinical use. The distinction is important when healthcare providers evaluate the evidence behind a diagnostic service.
Commercial adoption will also depend on reimbursement and healthcare workflow. Physicians and patients need to understand when the test is appropriate, how samples are collected, how results are reported and what follow-up is required. Insurers may evaluate clinical utility and cost-effectiveness before expanding coverage.
Cyted has not disclosed a new nationwide reimbursement agreement or a commercial revenue forecast arising from DETECT-ME. The October announcement provides clinical validation evidence rather than a new FDA authorization or a guaranteed change in payer coverage. Continued real-world studies may help establish whether the test improves appropriate screening and uses endoscopy resources effectively.
What evidence would establish EndoSign’s value beyond diagnostic accuracy?
The next important question is whether EndoSign increases appropriate diagnosis among people who would otherwise remain unscreened. A prospective accuracy study can show whether the test agrees with an established reference standard, but it does not establish that offering the test improves screening participation or leads to earlier treatment. Those outcomes require evidence from implementation studies and clinical pathways.
Researchers will also need to understand how the assay performs when used in routine primary care populations with different disease prevalence from specialist validation cohorts. Sensitivity, specificity and patient tolerability may remain similar, but predictive values and the number of confirmatory procedures can change substantially. Economic assessments will need to consider both test costs and downstream healthcare use.
The reported 100% detection of dysplasia and cancer is a potentially important finding, but its precision will remain uncertain until detailed subgroup results are available. Larger studies could provide stronger confidence that clinically consequential disease is rarely missed. Longer-term follow-up would also help establish whether the approach contributes to earlier diagnosis of esophageal adenocarcinoma.
Cyted’s DETECT-ME data provide meaningful US evidence supporting a non-endoscopic pathway for identifying Barrett’s esophagus. The study demonstrated encouraging overall accuracy, high sampling success and favorable tolerability across multiple clinical centers. The main remaining challenge is to demonstrate that this diagnostic performance translates into accessible, cost-effective screening without replacing the confirmatory role of endoscopy.
For Cyted Health, the October 2026 results strengthen the scientific basis for its molecular diagnostics business and its expansion in the United States. The clinical opportunity is substantial because many people at increased risk of Barrett’s esophagus do not undergo conventional screening. The company’s future differentiation will depend on whether EndoSign can help close that detection gap while maintaining reliable performance in routine medical practice.
